Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer

New England Journal of Medicine

Volumn 340, Issue 2, 1999, Pages 77-84

  Hartmann, Lynn C ^a   Schaid, Daniel J ^a   Woods, John E ^a   Crotty, Thomas P ^b   Myers, Jeffrey L ^a   Arnold, P G ^a   Petty, Paul M ^a   Sellers, Thomas A ^a   Johnson, Joanne L ^a   McDonnell, Shannon K ^a   Frost, Marlene H ^a   Jenkins, Robert B ^a   Grant, Clive S ^a   Michels, Virginia V ^a  

^a MAYO CLINIC   (United States)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; FOLLOW UP; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; BREAST; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MASTECTOMY; MASTECTOMY, SIMPLE; MASTECTOMY, SUBCUTANEOUS; MIDDLE AGED; NUCLEAR FAMILY; PROBABILITY; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0033552904     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199901143400201     Document Type: Article

References (39)

1. Lopez MJ, Porter KA. The current rok of prophylactic mastectomy. Surg Clin North Am 1996;76:231-42.
2. Pennisi VR. Redefined indications for subcutaneous mastectomy in patients with benign breast disease. Aesthetic Plast Surg 1986;10:101-4.
3. Prophylactic mastectomy. Arlington Heights, Ill.: American Society of Plastic and Reconstructive Surgeons, June 1994.
4. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. JAMA 1997;277:997-1003.
5. Statement of the American Society of Human Genetics on genetic testing for breast and ovarian cancer predisposition. Am J Hum Genet 1994; 55:i-iv.
6. Hoskins KF, Stopfer JE, Calzone KA, et al. Assessment and counseling for women with a family history of breast cancer: a guide for clinicians. JAMA 1995;273:577-85.
7. Hicken NF. Mastectomy: clinical pathologic study demonstrating why most mastectomies result in incomplete removal of mammary gland. Arch Surg 1940;40:6-14.
8. Ziegler LD, Kroll SS. Primary breast cancer after prophylactic mastectomy. Am J Clin Oncol 1991;14:451-4.
9. Eldar S, Meguid MM, Beatty JD. Cancer of the breast after prophylactic subcutaneous mastectomy. Am J Surg 1984;148:692-3.
10. Goodnight JE Jr, Quagliana JM, Morton DL. Failure of subcutaneous mastectomy to prevent the development of breast cancer. J Surg Oncol 1984;26:198-201.
11. Pennisi VR, Capozzi A, Perez FM. Subcutaneous mastectomy data: a preliminary report. Plast Reconstr Surg 1977;59:53-6.
12. Pennisi VR, Capozzi A. Subcutaneous mastectomy data: a final statistical analysis of 1500 patients. Aesthetic Plast Surg 1989;13:15-21.
13. Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis -effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997; 336:1465-71.
14. Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol 1998;16:979-85.
15. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86.
16. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, adopted on February 20, 1996. J Clin Oncol 1996;14:1730-6.
17. Understanding gene testing. Bethesda, Md.: National Cancer Institute, December 1995. (NIH publication no. 96-2905.)
18. Olopade OI, Cummings S. Genetic counseling for cancer: PPO Update 1996;10:1-13.
19. Woods JE. Subcutaneous mastectomy: current state of the art. Ann Plast Surg 1983;11:541-50.
20. Idem. Breast reconstruction: current state of the art. Mayo Clin Proc 1986;61:579-85.
21. Bilimoria MM, Morrow M. The woman at increased risk for breast cancer: evaluation and management strategies. CA Cancer J Clin 1995;45: 263-78.
22. Levitan M, Montagu A. Textbook of human genetics. 2nd ed. rev. New York: Oxford University Press, 1977:410.
23. Sham P. Statistics in human genetics. New York: John Wiley, 1997:32.
24. Ernster VL. Epidemiology and natural history of ductal carcinoma in situ. In: Silverstein MJ, ed. Ductal carcinoma in situ of the breast. Baltimore: Williams & Wilkins, 1997:23-33.
25. Fonseca R, Hartmann LC, Petersen IA, Donohue JH, Crotty TB, Gisvold JJ. Ductal carcinoma in situ of the breast. Ann Intern Med 1997; 127:1013-22.
26. Kosary CL, Ries LAG, Miller BA, Hankey BF, Harras A, Edwards BK, eds. SEER cancer statistics review, 1973-1992: tables and graphs. Bethesda, Md.: National Cancer Institute, 1995. (NIH publication no. 96-2789.)
27. United States life tables: 1959-61. Vol. 1. No. 1. Washington, D.C.: Government Printing Office, December 1964. (PHS publication no. 1252.)
28. U.S. decennial life tables for 1969-71. Vol. 1 No. 2. Washington, D.C.: Government Printing Office, 1970. (DHHS publication no. (PHS) 75-1150.)
29. U.S. decennial life tables for 1979-81. Vol. 1. No. 4. Washington, D.C.: Government Printing Office, 1980. (DHHS publication no. (PHS) 87-1150-4.)
30. Bondy ML, Lustbader ED, Halabi S, Ross E, Vogel VG. Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst 1994;86:620-5.
31. Benichou J, Gail MH, Mulvihill JJ. Graphs to estimate an individualized risk of breast cancer. J Clin Oncol 1996;14:103-10.
32. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
33. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98-101.
34. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998;352:93-7.
35. Couch FJ, DeShano ML, Blackwood MA, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997;336:1409-15.
36. Schaid DJ. Re: probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 1997;89;1632-4.
37. Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 1997;89:227-38.
38. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer: implications for risk prediction. Cancer 1994; 73:643-51.
39. Stefanek ME, Helzlsouer KJ, Wilcox PM, Houn F. Predictors of and satisfaction with bilateral prophylactic mastectomy. Prev Med 1995;24:412-9.